ClinicalTrials.gg
RecruitingNCT05970666Updated Feb 28, 2024

Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma

A Phase 2 interventional study of TACE with adebrelimab and bevacizumab in Adebrelimab, Hepatocellular Carcinoma and Transformation, sponsored by The First Affiliated Hospital of Xiamen University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-02-28.

Sponsored by The First Affiliated Hospital of Xiamen University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
71
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies testing adebrelimab in Carcinoma, Hepatocellular — 12 open to participants now, 12 under way, 1 of them phase 3. adebrelimab · Carcinoma, Hepatocellular.

Planned enrollment
5th of 13
71 · median 52
Started
2023
with 2 others
Phase 2
8 of 13
7 open now
Primary completion
2026-11
later than 5 of 11 live
Registered
3rd of 13
by date
Lead sponsor
1 of 13
The First Affiliated Hospital of Xiamen University

Among the 13 studies testing adebrelimab in Carcinoma, Hepatocellular, this one is the 5th largest by planned enrollment, is one of 3 that started in 2023, is one of 8 in phase 2, reaches primary completion later than 5 of the 11 other live ones, and was the 3rd registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

12 of the 13 studies testing adebrelimab in Carcinoma, Hepatocellular are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

About adebrelimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing adebrelimab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of TACE combined with adebrelimab and bevacizumab transformation in unresectable hepatocellular carcinoma

03

Conditions studied

  • Adebrelimab
  • Hepatocellular Carcinoma
  • Transformation
  • Bevacizumab
  • TACE
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: 18 \~ 75, both male and female;
  2. Strictly comply with the primary liver cancer diagnosis and treatment standard (2022 edition) clinical diagnosis criteria or primary hepatocellular carcinoma diagnosed by pathological histology or cytology examination, and at least one (according to the RECIST1.1 standard, the spiral CT scan of 10mm or short diameter of 15mm);
  3. Patients without previous systematic treatment and inoperable resection / radical ablation surgery, but who can tolerate TACE;
  4. The CNLC stage is Ⅱa-Ⅲb stage;
  5. The grade of liver function is A grade or B grade (5-7 points);
  6. The PS score is 0-1 points;
  7. Expected survival period of 12 weeks;
  8. If the patient has active virus (HBV) infection: HBV-deoxyribonucleic acid (DNA) must be \<2000 IU / mL (if the study site has only copy / mL testing units, Must be \<12500 copy / mL), And received at least 14 days before initiating anti-HBV treatment (according to local standard therapy, e. g. entecavir) and willing to receive antiviral treatment throughout the study; virus (HCV) ribonucleic acid (RNA) positive patients must receive antiviral treatment according to local standard treatment guidelines and liver function within grade 1 elevation;
  9. Main organs function are normal and meet the following criteria: (1) The blood routine examination standards should be met with: (no blood transfusion within 14 days) A. (HB), 90g / L, B. White blood cell count (WBC) 3109 / L C. (ANC) 1.5109 / L, D. (PLT) 80109 / L;(2) Biochemical examination shall meet the following standards: A. (BIL) \<1.5 times the value (ULN); B. Glutamic gamma aminotransferase () and glutamate aminotransferase AST \<5 ULN; C. Serum creatinine (Cr)≤1.5ULN;
  10. Women of childbearing age must have negative pregnancy test (serum) or urine HCG within 7 days before enrollment and are willing to use appropriate during treatment and 24 weeks after the last administration of test drug; for men, surgical sterilization or agree to use appropriate contraception during and 24 weeks after the last administration of trial drug;
  11. The subjects volunteered to join the study and had good compliance with the follow-up.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating women;
  2. The pathology is clearly cholangiocytic carcinoma or mixed cell carcinoma;
  3. Diffuse liver cancer;
  4. Patients with diseases, organ / hematopoietic stem cell transplantation or other malignant tumors (except for cured basal skin cell carcinoma and cervix carcinoma in situ);
  5. Patients with consciousness disorders or unable to cooperate with the treatment, combined with patients with mental illness;
  6. Patients who have participated in other clinical trials in the recent three months;
  7. Previous history of other or have received targeted therapy and other / PD-L1 inhibitor therapy;
  8. Received major surgery or chemotherapy or other systemic therapy for target lesions (including not limited to radiation therapy, ablation therapy, etc.) within 1 month prior to enrollment;
  9. Use of or systemic hormone therapy within 14 days before enrollment to achieve immunosuppressive purposes (dose> 10mg / day prednisone or other efficacy hormones);
  10. Liver function was graded as C, which could not be improved by liver care treatment;
  11. esophageal (gastric fundus) varices rupture and bleeding within 1 month before treatment;
  12. Uncorrectable coagulopathy and severe blood abnormalities, with severe bleeding tendency. count \<50109 / L and severe coagulation abnormalities against surgery (anticoagulation therapy and / or anticoagulant therapy should be stopped for more than 1 week before radiation therapy);
  13. A stubborn amount of ascites, pleural fluid, malignant fluid;
  14. Active infection, especially the inflammation of the biliary tract system;
  15. Severe functional failure of the liver, kidney, heart, lung, brain and other major organs;
  16. Previously allergic to PD-1 / PD-L1 mAb / any component of the targeted drug or other similar trials;
  17. Patients with hypertension who cannot be reduced to the normal range by antihypertensive medication (systolic blood pressure> 140 mmHg, diastolic blood pressure> 90 mmHg);
  18. Previous severe cardiovascular disease, including but not limited to the following diseases: myocardial ischemia or myocardial infarction, poorly controlled arrhythmia (including 450 ms in men and 470 ms in women); cardiac dysfunction by , or cardiac ultrasound indicating (LVEF) \<50%;
  19. Patients with positive urinary protein (urinary protein test of 2 + or above, or 24-hour urinary protein quantification of> 1.0g);
  20. Failure to swallow tablets, malabsorption syndrome, or any condition affecting gastrointestinal absorption;
  21. According to the discretion of the investigator, patients with other concomitant diseases that seriously endanger patient safety or affect the completion of the study;
  22. Patients with radiotherapy, targeted therapy, and other to immunotherapy.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
71 participants (estimated)

Study arms

  • Experimental
    Single arm

    Drug: TACE with adebrelimab and bevacizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Objective response rate(ORR)

    Refers to the proportion of all subjects with the best overall response (BOR) as complete remission (CR) or partial remission (PR) according to mRECIST 1.1 criteria.

    Time frame: Up to 2 years

  2. Occurence of AE and SAE

    Occurence of Adverse Event (AE) and Serious Adverse Event (SAE) (NCI CTCAE 5.0)

    Time frame: Up to 2 years

Secondary outcomes

  1. Radical (R0) resection rate after conversion therapy

    The cut margin had no residual cancer cells

    Time frame: Up to 2 years

  2. percent conversion

    The ates of conversion to operable patients in inoperable patients

    Time frame: Up to 2 years

  3. Pathological complete response rate (pCR)

    The rate of no remaining tumor cells in the excised tissue samples

    Time frame: Up to 2 years

  4. Major pathological response rate (MPR)

    The ratio of the tumor cells active in the removed tissue samples is less than 10%.

    Time frame: Up to 2 years

  5. Progression-free survival (PFS)

    PFS was defined as the subject's date from the date of the first dose to the date of the first documented tumor progression (as assessed by mRECIST criteria, with or without continuation of treatment) or the date of death from any cause, whichever occurred first.

    Time frame: Up to 2 years

  6. Disease control rate(DCR)

    Refers to the proportion of all subjects with the best overall response (BOR) according to mRECIST criteria as complete remission (CR), partial remission (PR) and stable disease (SD).

    Time frame: Up to 2 years

  7. Relapse-free survival time (RFS)

    Time from date of cure surgery to time of recurrence or death

    Time frame: Up to 2 years

  8. Overall survival(OS)

    Defined as the time from the date of the first dose to the death of the subject from any cause.

    Time frame: Up to 2 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Nov 2026, 36 months after the start.

Of 352 non-industry phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 78. This study's planned 36 months is below that.

Counting every sponsor, half of 432 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2023
First posted
Aug 1, 2023
StartActual
Nov 15, 2023
Primary completionEst.
Nov 15, 2026
CompletionEst.
Nov 15, 2026
Last update
Feb 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05970666
Responsible party
Jianbo Chen (director, The First Affiliated Hospital of Xiamen University) — Principal investigator
First posted
Aug 1, 2023
Start date
Nov 15, 2023
Primary completion
Nov 15, 2026 (estimated)
Completion
Nov 15, 2026 (estimated)
Last update
Feb 28, 2024

Study contacts

Jianbo Chen
Contact
274439002@qq.com
15605921022
Jianbo Chen
principal investigator · The First Affiliated Hospital of Xiamen University
Feng Ye
principal investigator · The First Affiliated Hospital of Xiamen University
congren Wang
study director · Quanzhou First Hospital
Qinghe Cai
study director · Affiliated Hospital of Putian University
Jiafei Chen
study director · Putian First Hospital
Yongzhong Wang
study director · Sanming Second Hospital
Feng Lin
study director · Ningde Mindong Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Adebrelimab · Bevacizumab

Start the discussion